What is LOPJLB’s current signal on CRDF?

LOPJLB’s latest quantitative signal on Cardiff Oncology, Inc. (CRDF) is BUY in a RECOVERY regime. Signals are updated daily.

What market regime is CRDF in?

Cardiff Oncology, Inc. (CRDF) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does Cardiff Oncology, Inc. (CRDF) do?

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials …

Where is Cardiff Oncology, Inc. based / listed?

Cardiff Oncology, Inc. is based in US, listed on NASDAQ.

Cardiff Oncology, Inc. (CRDF)

Healthcare · Biotechnology · NASDAQ · US

$1.00+13.64%Close

BUYRECOVERY · day 1

[SCORES & PROFILE]

FUND: 6
VALUE: 6
GROWTH: 19
GARP: 7
TYPE: Balanced

Composite of Value · Growth · GARP

ROIC-61.8%

REV YoY-

ROE-103.1%

EPS YoY-

ROA-107.3%

GROSS

100

-8320

NET

-7884

[VALUATION]

P/E TTM-1.66

P/E FWD-

SECTOR PE22.66

INDUSTRY PE17.07

P/B2.57

P/FCF-

EV/EBITDA-1.75

EV/EBIT-

PEG-

FCF YIELD-

RISK

INT COV-

D/E1.72

ALTMAN Z-

CURR RATIO3.30

ND/EBITDA-

BETA1.44

Cardiff Oncology, Inc. (CRDF)

Key stats

Sector peers

Industry peers

Prediction markets

FUNDAMENTALS

Company news